Zuranolone for the Treatment of Postpartum Depression

This Practice Advisory is provided to address the August 4, 2023, decision by the U.S. Food and Drug Administration (FDA) to approve zuranolone. Zuranolone is a neuroactive steroid gamma-aminobutyric acid (GABA) A receptor positive modulator, and the first oral medication indicated to treat postpartum depression in adults 2.